Nasdaq · Healthcare

Karyopharm Therapeutics Inc. (KPTI)

As-reported financials and recent SEC filings for Karyopharm Therapeutics Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$146.1M

Net income

$-196.0M

Net margin

-134.2%

Diluted EPS

$-17.93

ROE

66.9%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$146.1M	$145.2M	$146.0M	$157.1M	$209.8M
Gross profit	—	—	—	—	—
Operating income	$-90.7M	$-119.4M	$-129.5M	$-142.2M	$-98.3M
Net income	$-196.0M	$-76.4M	$-143.1M	$-165.3M	$-124.1M
Diluted EPS	$-17.93	$-14.00	$-18.79	$-22.22	$-16679.85

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

SCHEDULE 13G/A2026-06-05

8-K2026-05-28

S-82026-05-27

S-82026-05-27

42026-05-26

42026-05-26

42026-05-26

42026-05-26

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on KPTI

Search Karyopharm Therapeutics Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.